Loading...
•
Jun 30, 2024
OraSure Q2 2024 Earnings Report
Reported Q2 2024 results with revenue of $54.3 million and GAAP EPS of $(0.01).
Key Takeaways
OraSure Technologies reported a 36% decrease in total net revenues to $54.3 million compared to Q2 2023. Core revenues decreased by 7% year-over-year. The company is focusing on strengthening its foundation, elevating its core business, and accelerating profitable growth through innovation and cost efficiency.
OraQuick® HCV Self-test is the first globally to earn WHO pre-qualification.
Strong momentum with Syphilis Health Check™ launch.
Expanding Sample Management applications into saliva-based liquid biopsy.
Company remains on track to achieve operating cash flow break-even for the core business by the end of 2024.
Revenue by Segment
Forward Guidance
The Company is guiding to Q3 2024 revenues of $37 to $41 million, which includes Core revenues of $36 to $39 million and InteliSwab® revenues of $1 to $2 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...